| abstract |
The invention discloses application of the reagent of in situ hybridization detection circular rna circRNF13 on preparing Dendritic cell patient's prognosis preparation.Effect of follow-up visit by telephone has been carried out to 88 Dendritic cell patients, in detail inquired they start time, treatment, whether there is or not recurrence, whether there is or not suffer from other diseases, recurrence and death time etc. again, and register life span and state, and to the survival analysis that the expression of circRNF13 in Dendritic cell tissue and the life span of patient and state carry out, it is found that the patient for not expressing circRNF13 in Dendritic cell tissue is significantly shorter than circRNF13 the mean survival times and expresses higher patient.Illustrate that circRNF13 is one and the relevant molecular labeling of Dendritic cell prognosis, circRNA expression is low or does not express, patient's poor prognosis. |